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Objectives. This study was defined as a pilot investigation of
the usefulness and safety of intravenous diltiazem as adjunctive
therapy to tissue plasminogen activator in acute myocardial
infarction, followed by oral therapy for 4 weeks.
Background. Experimental studies have documented that cal-
cium antagonists protect the myocardial cell against the damage
caused by coronary artery occlusion and reperfusion, yet no
benefits have been conclusively demonstrated in acute myocardial
infarction (AMI) in humans.
Methods. In this pilot study, 59 patients with an AMI treated
with tissue-type plasminogen activator (t-PA) were randomized,
double blinded, to intravenous diltiazem or placebo for 48 h,
followed by oral therapy for 4 weeks. The primary objective was to
detect an effect on indices of regional left ventricular function and
perfusion. Patients were also closely monitored for clinical events,
coronary artery patency and indices of infarct size and of left
ventricular function.
Results. Creatine kinase elevation, Q wave score, global and
regional left ventricular function and coronary artery patency at
48 h were not significantly different between the diltiazem and
placebo groups. A greater improvement observed in regional
perfusion and function with diltiazem was likely explained by
initial larger defects. Diltiazem, compared to placebo, reduced
the rate of death, reinfarction or recurrent ischemia at 35 days
from 41% to 13% (p 5 0.027) and prevented the need for an
urgent intervention. The rate of death or myocardial infarction
was reduced by 65% (p 5 0.15). These benefits could not be
explained by differences in baseline characteristics such as age,
site and extent of infarction, time of inclusion or concomitant
therapy. Heart rate and blood pressure were reduced through-
out the study with active diltiazem treatment. Side effects of
diltiazem were bradycardia and hypotension that required
transient or permanent discontinuation of the study drug in
27% of patients, vs. 17% of patients with placebo.
Conclusions. A protective effect for clinical events related to
early postinfarction ischemia and reinfarction was suggested in
this study, with diltiazem administered intravenously with t-PA
followed by oral therapy for 1 month, with no effect on coronary
artery patency and left ventricular function and perfusion.
(J Am Coll Cardiol 1998;32:620–8)
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Experimental data strongly support a benefit of calcium antag-
onists in acute myocardial infarction (AMI) (1). This pharma-
cologic approach can preserve high energy phosphate metab-
olism (2,3) and mitochondrial ultrastructure (4), prevent
myocardial stunning, regional dysfunction (5,6) and neutrophil
accumulation (7) and reduce infarct size in the reperfused
(7–10) and nonreperfused myocardium (11–14). The effects
are greater with shorter duration of ischemia (14,15) and when
treatment is initiated before coronary occlusion (8,10), before
reperfusion (2,7,10,14) or early during the ischemic state
(14,16).
In clinical practice diltiazem is used mainly for its anti-
ischemic effect. Studies performed during the evolving AMI
have failed to document a benefit with the use of calcium
antagonists (17–23). In most of these studies the drugs were
administered outside the context of reperfusion. Two studies
have described their effect in conjunction with mechanical
revascularization. In one study (22), a deleterious effect of
diltiazem on enzymatic infarct size and mortality was sug-
gested. The other study (23) was a retrospective analysis of
the impact on survival of medication used at the time of
reperfusion and suggested no favorable influence of calcium
antagonists.
The present study was undertaken to investigate the para-
dox of benefit in experimental settings but no clinical gain in
patients with an AMI.
Methods
Inclusion and Exclusion
A total of 60 patients with an evolving AMI and ST-
segment elevation were entered into the study. One patient
allocated to placebo was excluded from the analysis because he
rapidly developed cardiogenic shock before the study drug and
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before tissue-type plasminogen activator (t-PA) could be ini-
tiated. The entry criteria were evolving chest pain within the
previous 6 h with ST-segment elevation 1 mm or more in two
or more adjacent leads, the absence of a contraindication to
thrombolysis or to diltiazem and a signed patient consent form.
Contraindications to fibrinolysis included: uncontrolled hyper-
tension .220 systolic and .110 diastolic, active peptic ulcer,
trauma or surgery within the previous 2 weeks, stroke within
the previous 3 months or a bleeding disorder. Contraindica-
tions to diltiazem administration were cardiogenic shock,
pulmonary edema, congestive heart failure, atrial flutter or
fibrillation and first, second or third atrioventricular block.
Design and Objectives
This pilot study included a relatively homogeneous patient
population with an evolving ST-segment elevation AMI with
the objective of detecting a potential protective effect of
diltiazem. Because no reliable markers of infarct size exist in
humans, a variety of methods was used to evaluate the size of
the area of necrosis relative to the area at risk. The objective
was to detect improvement in the global contraction and
perfusion score with diltiazem compared with placebo, with
consistent trends observed in other parameters, and more
important in clinical evolution, regrouping death, reinfarction
and recurrent ischemia with ST-segment changes or the need
for an urgent intervention. This latter goal was based on the
well-documented antiischemic properties of the drug and on
favorable effects observed in non-Q-wave AMI (24). The
incidence of congestive heart failure, bradyarrhythmia and
hypotension, bleeding complications and the results of the
exercise tests were analyzed. All patients were carefully mon-
itored during their hospitalization and for 4 weeks following
hospital discharge. The study was divided into four study
periods: an acute phase from admission to 4 h, a subacute
phase from 4 to 48 h, an intermediate observation period until
hospital discharge, including coronary angiography between
days 2 and 4, radionuclide studies and treadmill exercise
testing between days 5 and 7 and a follow-up phase extending
from hospital discharge to 35 days. Figure 1 provides the
outline of the investigation performed during the various study
periods.
Study Drugs and Other Medications
Patients were randomized to receive double blinded either
diltiazem hydrochloride or placebo in addition to aspirin,
heparin and t-PA. Diltiazem was administered as an intrave-
nous bolus of 10 mg in 10 min followed by an infusion at a rate
of 10 mg/h for 48 h. Oral therapy with diltiazem 120 mg three
times a day (360 mg daily dose) or placebo was started 8 h after
the discontinuation of the infusion and continued until the
4-week follow-up visit. Plasma levels of diltiazem measured by
high-performance liquid chromatography on blood obtained
during the steady-state intravenous infusion 24 to 36 h after the
start of therapy averaged 371 6 162 ng/ml. Tissue-type plas-
minogen activator (Activase, Genentech Canada, Burlington,
Ontario) was initiated concomitantly with the bolus injection
of the study drug as a 7 mg I.V. bolus in 3 min followed by
53 mg in 57 min, 20 mg in 1 h and 10 mg/h for 2 h. The dose
of aspirin was 325 mg orally at admission and daily thereafter.
An infusion of heparin was also initiated at the same time in all
patients at a rate of 1,000 U/h with no initial bolus injection.
An activated partial thromboplastin time was obtained after
12 h to titrate the infusion rate of heparin to two times the
control values. The heparin infusion was generally discontin-
ued after 72 h.
A methodology was designed to ensure safe and blind
administration of diltiazem. A volume of 500 ml of normal
saline was rapidly administered when symptomatic hypoten-
sion or heart rate below 55 beats/min was experienced by
patients from either treatment group. If the hemodynamic
condition was not corrected by this measure, the infusion rate
of the study drug was decreased by 50%. In the absence of
improvement or in the presence of more severe bradyarrhyth-
mia such as atrioventricular dissociation or second degree
atrioventricular block, the study drug was discontinued then
resumed after the condition was corrected. Recurrence of
the abnormal state after a second initiation of the study
drugs or appearance of more severe hypotension or of
congestive heart failure or cardiogenic shock during study
drug administration mandated the permanent discontinua-
tion of the study drug.
The use of cardiac medications was left to the discretion of
the treating physician with the exception of calcium antago-
nists, which were prohibited throughout the study. During the
acute and subacute phases, intravenous nitroglycerin was ad-
ministered in 19 patients randomized to the diltiazem group
and in 23 patients randomized to the placebo group, beta-
blockers in 12 and 22 patients, respectively, and angiotensin-
converting enzyme inhibitors in 6 and 12 patients.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CK 5 creatine kinase
t-PA 5 tissue-type plasminogen activator
Figure 1. Outline of the investigation performed during the various
study periods. 99m-Tc SPECT 5 technetium-99m sestamibi single
emission-computed tomography.
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Clinical Evaluation
Clinical events considered in addition to events related to
ischemia were events related to left ventricular dysfunction
including congestive heart failure, acute pulmonary edema and
cardiogenic shock. The diagnosis of infarct extension required
a new episode of prolonged chest pain, new electrocardiogram
(ECG) changes and reelevation of plasma levels of creatine
kinase (CK) and of CK MB fraction. Early ischemia was
defined as a recurrence of ischemic chest pain 12 h or more
after the initial infarct with documentation of transient ST-T
changes or with the need for an urgent catheterization with a
view to coronary artery bypass surgery or coronary angioplasty.
An intervention procedure on the indication of coronary
anatomy without symptoms was not considered as an end
point.
Electrocardiography
Infarcts were classified as inferior or anterior based on
leads with ST-segment elevation on the 12-lead ECG, and on
the location of the culprit lesion and wall motion abnormality
on the angiograms. An index of infarct size developed by
Selvester et al. (25) and Wagner et al. (26) was calculated. This
score correlates with postmortem infarct size: r 5 0.80 for
anterior infarcts (26), 0.74 for inferior infarcts (27) and 0.72 for
posterolateral infarcts (28). The score considers the duration
and magnitude of each deflection of the QRS complex. The
sum of ST-segment elevation was calculated on the ECG
performed before initiation of treatment and the Q wave score
on subsequent ECGs as indices of area at risk and of area of
necrosis, respectively (29–33).
A treadmill exercise test using the Naughton protocol,
limited to a workload of 5 mets or to 80% of maximal
age-predicted heart rate, was also performed before hospital
discharge in the 49 patients with no contraindications. The
criterion for a positive test was ST-segment depression 1 mm
or more compared to baseline.
Radionuclide Ventriculography
Equilibrium radionuclide ventriculography was performed
using in vivo red blood cell labeling with 1 GBq (27 mCi) of
technetium-99m (Tc-99m) pertechnetate. Segmental wall mo-
tion was assessed visually in five sectors in three standard views
(left anterior oblique-best septal, anterior, and left lateral) and
graded: 0 5 hyperkinesis, 1 5 normal, 2 5 mild hypokinesis,
3 5 moderate hypokinesis, 4 5 severe hypokinesis, 5 5
akinesis and 6 5 dyskinesis. A wall motion score of the infarct
zone was calculated by averaging the scores for the sectors
involved in the acute infarct area on the initial angiogram and
by following the same zone on subsequent examinations. A
global score was calculated by adding the 15 individual scores
for each of the patients.
Technetium-99m Sestamibi Single Photon Emission
Computed Tomography (SPECT)
SPECT studies were obtained 2 to 4 h after injections of
1 GBq (27 mCi) Tc-99m sestamibi at the time thrombolytic
therapy was initiated, 16 to 36 h later and before hospital
discharge (after 5 to 7 days). Sixty-four projections were
acquired over a 360° variable elliptic orbit on a 64 3 64 3
16-byte matrix with a zoom of 1.44. Processing and image
analyses were performed by a methodology already described
(34,35). In summary, 25 regions of interest of equal size were
automatically drawn on the polar bidimensional map of each
patient. The relative uptake in each of these sectors was
determined and normalized to the sector with maximal value.
Values were compared to those of rest Tc-99m sestamibi
SPECT studies obtained from normal volunteers. A sector was
considered abnormal when normalized counts were more than
two standard deviations below the normal mean. Defect size
was calculated as the ratio of the number of abnormal sectors
to the total number of sectors. Defect intensity was defined as
the ratio of the average normalized counts in the abnormal
sectors to the corresponding normal means. A global defect
score index was calculated as the product of defect size and
defect intensity. These analyses were performed excluding
perfusion defects that were clearly distinct from the AMI
related to a previously well-documented myocardial infarction.
Statistical Analysis
The study was unblinded only after final adjudication of
all events and validation of the database. Results were
analyzed by the intention-to-treat principle. Per protocol,
the patient who rapidly developed cardiogenic shock before
the initiation of the study drug and of t-PA was excluded.
The sample size in this pilot study was estimated at 30
patients per group to detect with 90% power a 50% greater
improvement in the global contraction and perfusion score
with diltiazem vs. placebo.
Comparisons of baseline characteristics between the two
study groups were performed with the unpaired Student t test
and chi-square statistics. These tests were also used to compare
clinical and laboratory data. An analysis of variance was
performed when more than two sets of data were compared for
the evaluation of heart rate and blood pressures and of
markers of left ventricular function and perfusion. Odd ratios
and 95% confidence interval (CI) were calculated for the
clinical event rates. A Kaplan–Meier survival curve was con-
structed to compare survival without myocardial infarction and
without recurrent ischemia and analyzed by the log-rank
statistic. A proportional hazard regression with the Cox model
was also performed for potential confounding effects of age
and sex, site and extent of ST-segment elevation, size of the
perfusion defect at admission, time to thrombolysis and other
drugs used. Correlations were also made between the ECG
findings and the radionuclide data at admission and 1 and 4
weeks later in the two study groups. Nominal p values of less
than 0.05 were considered statistically significant. Values are
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means and standard deviations except when otherwise speci-
fied.
Results
Study Population and Study Groups
The mean age of the population was 58 years old (range 34
to 74) with 10 women and 49 men. Twenty-nine patients were
current smokers and five had treated diabetes mellitus. A
previous history of coronary disease was present in 20 patients.
The thrombolytic treatment was initiated an average of 163 6
58 min (range 56 to 370 min) after the onset of chest pain,
slightly later in the diltiazem group (NS). The baseline char-
acteristics were otherwise evenly distributed in the two study
groups (Table 1). The distribution of anterior vs. inferior
infarcts was also similar. The amount of ST-segment elevation
was nonsignificantly greater in the diltiazem group, particularly
in anterior infarcts 19.8 6 11 mm vs. 14.7 6 9 mm (Table 2).
This corresponded in anterior AMI to more extensive perfu-
sion defect in patients at the SPECT study, 24.2 6 9 vs. 11.3 6
7 in the placebo group (p , 0.002), and to a greater regional
contraction score at the radionuclide angiogram, 4.3 6 0.6 vs.
3.4 6 1.5 (Table 3).
Cross-correlation Between Various Parameters
The correlation matrix observed between the various mea-
surements at baseline and at various periods of the study showed
a significant correlation between most parameters. Exceptions
were: 1) ejection fraction at 24 h and sum of ST-segment
elevation at admission and QRS scores at 24 h and 7 days and 2)
7-day perfusion defect score and sum of Q wave at 24 h and 7
days. The best correlation coefficients were between admission
sum of ST-segment elevation and subsequent Q-wave and con-
traction scores (p 5 0.0001), between admission perfusion defect,
peak CK elevation and final contraction score (p 5 0.0001) and
between the final contraction score, Q-wave score and ejection
fraction (p 5 0.0001). The sequential changes observed with each
investigation method also correlated well.
Clinical and Electrocardiographic Data
Figure 2 illustrates the serial changes in heart rate and
blood pressure during treatment and Table 2 describes the
clinical and electrocardiographic data. Diltiazem reduced
heart rate and systolic and diastolic blood pressures at all
times, and consequently the pressure rate product. Peak total
CK and CK-MB elevations, time to peak elevation and time to
relief of pain were all similar between the two groups. Beta-
blockers and converting-enzyme inhibitors were used less
frequently in the diltiazem-treated patients. The sum of ST-
segment elevation was slightly greater at baseline in the
diltiazem group, more specifically in anterior infarcts (19.8 6
11 vs. 14.7 6 9); the sum of Q and the Wagner scores at 24 h
and at 1 week were, however, the same in the two study groups.
The sum of ST-segment elevation correlated with the Wagner
score at 24 h (1.897 6 0.18) and at 1 week (1.668 6 0.175). This
correlation was similar in diltiazem (1.73 6 0.198) and placebo
patients (2.155 6 0.153), considering all infarcts and also
anterior infarcts alone (0.684 6 0.226 and 20.113 6 0.303,
respectively).
Myocardial Perfusion
The size and score of the perfusion defect decreased in the
two study groups between admission and 24 h and again
between 24 h and 7 days, suggesting a decreasing infarct size
relative to the area at risk (Table 3). The magnitude of the
Table 1. Baseline Characteristics
Diltiazem
(n 5 30)
Placebo
(n 5 29) p Value
Age (yr) 57 6 11 60 6 9 NS
Male patients (%) 25 (83%) 24 (83%) NS
Smokers 16 (52%) 13 (45%) NS
Diabetes mellitus 2 (6%) 3 (10%) NS
Previous HBP 6 (19%) 6 (21) NS
Previous CAD 10 (33%) 10 (34%) NS
Site of AMI
Anterior 12 (40) 13 (45)
Inferior 18 (60) 16 (55) NS
Time from onset of pain to
thrombolysis (min)
175 6 64 151 6 48 0.12
CAD 5 coronary artery disease; HBP 5 high blood pressure.
Table 2. Clinical and Electrocardiographic Findings
Diltiazem
(n 5 30)
Placebo
(n 5 29) p Value
Time to pain relief (min) 41 6 65 51 6 70
Peak CK, IU/L 2,751 6 2,007 2,336 6 1,950 NS
Peak CK-MB, IU/L 315 6 230 249 6 161 NS
Time to peak CK-MB (h) 13 6 5 12 6 6 NS
Concomitant therapy
Aspirin 30 29 NS
Heparin 30 29 NS
Nitroglycerin 19 23 NS
ACE inhibitors 6 11 0.08
Beta-blockers 11 20 0.02
ECG
Admission
S ST (mm) 13.9 6 10 12.5 6 8 NS
Anterior MI 19.8 6 11 14.7 6 9 NS
Inferior MI 9.7 6 7 10.9 6 8 NS
24 h
S Q, mm 15.4 6 18 14.8 6 17 NS
Wagner score 4.5 6 3.3 4.1 6 3.4 NS
Anterior MI 5.2 6 3.7 4.8 6 3.5 NS
Inferior MI 3.9 6 3.0 3.5 6 3.4 NS
7 days
S Q, mm 15.3 6 19 11.1 6 24 NS
Wagner score 4.4 6 3.3 3.4 6 3.2 NS
Anterior MI 5.2 6 3.1 4.3 6 3.1 NS
Inferior MI 3.9 6 3.4 2.7 6 2.0 NS
ACE 5 angiotensin-converting enzyme; S 5 sum.
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decrease was significantly greater with diltiazem (p 5 0.04 for
all and 0.002 for anterior infarcts). The significance of this
finding, however, may be confounded by a greater initial defect
in the diltiazem group compared to placebo and a positive
correlation between the initial defect and subsequent improve-
ment (change in score 5 21.6 2 0.346 3 initial score, p 5
0.001).
Left Ventricular Function
Table 3 shows the results of the serial radionuclide angio-
grams obtained at 24 h, 7 days and 35 days. The analysis of
variance demonstrated no significant changes with time in
ejection fraction and in global and infarct zone contraction
scores between diltiazem and placebo-treated patients. In
anterior AMI, the ejection fraction at 24 h was 45.8 6 13%
with diltiazem and 44.3 6 13% with placebo, and at 6 weeks,
46.2 6 16% and 44.7 6 14%, respectively (NS).
Coronary Angiography
Thirteen diltiazem patients and 16 placebo patients had
multivessel disease. A Thrombolysis in Myocardial Infarction
trial grade 3 flow was present in 86% of diltiazem patients and
in 83% of placebo patients. The percent lumen diameter
reductions of the culprit coronary artery lesion were 74 6 18%
and 73 6 17%, respectively (p 5 NS).
Clinical Evolution
Table 4 gives the clinical evolution in the two study groups.
Death occurred in three patients, all in the placebo group; two
of these patients were receiving a beta-blocker. The causes of
death were cardiac rupture 21 h after randomization in one
patient, progressive congestive heart failure, refractory ventric-
ular arrhythmia and cardiogenic shock at day 3 in another and
recurrent pulmonary edema after 3 weeks in the third patient.
Extension of the infarction was diagnosed in three patients
randomized to diltiazem and in four randomized to placebo
(one in each study group receiving a beta-blocker) and recur-
rent ischemia in, respectively, one (on a beta-blocker) and seven
patients (five of them on a beta-blocker). None of the diltiazem
patients required urgent intervention compared to six (four on
a beta-blocker) of the placebo patients (angioplasty in two and
bypass surgery in four). Overall, balloon angioplasty or bypass
surgery, including elective indications, were performed in 9
diltiazem and 16 placebo patients. Cardiac failure was ob-
served in one diltiazem patient and in two placebo patients.
Mean heart rates achieved on the limited treadmill exercise
test performed before hospital discharge were 109 6 13
beats/min with diltiazem and 111 6 12 with placebo and a
workload of 4.5 6 1.3 and 4.1 6 1.1. ST-segment depression was
Figure 2. Heart rate and systolic and diastolic blood pressures before
and after the intravenous administration of diltiazem or placebo. The
standard errors are shown here. bpm 5 beats per minute. *p , 0.05,
†p , 0.01, ‡p , 0.001.
Table 3. Radionuclide Studies
Diltiazem Placebo p Value
Radionuclide ventriculogram
24 h
Ejection fraction (%) 50.2 6 11 49.8 6 14 NS
Contraction score
Global 15.3 6 13 15.9 6 13 NS
Infarct zone 3.6 6 1.3 3.1 6 1.6 NS
7 days
Ejection fraction (%) 46.2 6 12 48.1 6 14 NS
Contraction score
Global 11.5 6 13.3 12.7 6 12.5 NS
Infarct zone 3.0 6 1.4 2.6 6 1.4
6 weeks
Ejection fraction 47.3 6 11 47.7 6 15 NS
Contraction score
Global 14.9 6 13 14.5 6 13 NS
Infarct zone 3.1 6 1.5 2.9 6 1.6 NS
D Ejection fraction (24 h–35 days) 22.9 6 0.8 22.9 6 0.9 NS
D Contraction score (24 h–35 days)
Global 20.4 6 0.7 21.2 6 0.9 NS
Infarct zone 0.51 6 0.9 0.18 6 1.1 NS
Tc-99m SPECT studies
Score at entry 18.0 6 8 13.0 6 6 0.02
Score 24 h 13.1 6 8 10.1 6 6 NS
Score 7 days 9.6 6 7 7.2 6 6 NS
D Score entry (7 days) 28.3 6 5 25.6 6 4 0.04
Anterior AMI 212.4 6 3 25.9 6 4 0.002
Inferior AMI 26.5 6 4 25.4 6 5 NS
D 5 difference.
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observed in eight and five patients, respectively. Figure 3 shows
the Kaplan–Meier curves without myocardial infarction and
without recurrent ischemia. The two curves diverged in the first
24 h and kept diverging during follow-up, favoring diltiazem
(log-rank statistics 5 0.027). The stepwise Cox regression
model documented no predictive value of age, sex, anterior site
of the infarction, time to thrombolysis, defect score and sum of
ST-segment elevation at admission and concomitant medica-
tion used. The odds ratio for survival without myocardial
infarction was 0.35 with diltiazem (95% CI 0.05 to 1.79, p 5
0.15); for survival without infarction and without recurrent
ischemia the odds ratio was 0.22 (95% CI 0.05 to 0.90, p 5
0.015).
Drug Tolerance
Hypotension (blood pressure less than 100 mm Hg, or
rapidly falling by 20 mm Hg or more) and/or bradycardia and
supraventricular block with heart rate less than 55 beats/min
were recorded in 20 patients with diltiazem and required
temporary reduction (by 50%) or discontinuation of the infu-
sion in six patients and permanent discontinuation in two. It
was observed in 11 patients during the acute phase, in six
during the subacute phase and in four during the intermediate
phase. Hypotension was more frequent early and bradycardia
late. In the placebo group, six patients experienced hypoten-
sion during the acute phase and one during the subacute
phase; two other patients had bradyarrhythmia. The infusion
rate of placebo was reduced in four patients and discontinued
in one. Nausea was experienced by 12 diltiazem and 8 placebo
patients. Diltiazem patients more frequently developed a
hematoma at the site of femoral puncture (five vs. no patients
with placebo). Gastrointestinal bleeding occurred in two pa-
tients in each of the study groups and no patient had intracra-
nial bleeding. Only one patient required blood transfusion.
During the follow-up of 4 weeks after hospital discharge, one
patient discontinued oral therapy with diltiazem because of
gastric intolerance.
Discussion
This study was designed as a pilot study on the basis of
conflicting results observed between clinical and experimental
studies with calcium antagonists in AMI. The results showed
that intravenous diltiazem used as adjunctive therapy to t-PA
in AMI and followed by oral treatment significantly reduced
the recurrence of ischemic events at 35 days. Treatment,
however, had no detectable effects on the indices of ischemic
area, infarct size and left ventricular function (regional and
global).
Recurrent Ischemia and Recurrent
Myocardial Infarction
Recurrent ischemia, before the thrombolytic era, was ob-
served in 18% to 30% of patients and resulted in infarction
extension in 28% of patients (24,36). Thrombolytic therapy has
not improved these figures. Recurrent ischemia still occurs in
19% of patients and carries a risk of death or myocardial
infarction of 28%; the risk is 4% in patients without ischemia
(37). Reocclusion, observed in 15% to 30% of patients follow-
ing successful thrombolysis and myocardial infarction in 5% to
Figure 3. Percent cumulative survival without myocardial infarction
and without recurrent ischemia (top), and percent cumulative survival
without myocardial infarction (bottom) in patients randomized to
diltiazem or to placebo.
Table 4. Clinical Outcome Events
Diltiazem Placebo Odds Ratio (95% CI) p Value
Death 0 3 — —
MI 3 4 — —
Recurrent ischemia 1 7 0.11 (0.02–0.97) 0.02
Urgent intervention 0 6 0.00 (0.00–0.74) 0.009
Death/MI 3 7 0.35 (0.05–1.79) 0.15
Death/MI/recurrent ischemia 4 12 0.22 (0.05–0.90) 0.027
Death/MI/urgent intervention 3 13 0.14 (0.02–0.62) 0.003
All interventions 9 16 0.35 (0.10–1.15) 0.052
MI 5 myocardial infarction extension, CI 5 95% confidence interval.
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10% of patients, is associated with an impaired short- and
long-term prognosis with an event rate at 1 year approaching
70% (38,39).
In the present study, 48 h of diltiazem therapy initiated with
t-PA and followed by oral therapy reduced the odds of death,
myocardial infarction or recurrent ischemia at 35 days by 78%.
The small number of deaths and myocardial infarction pre-
vents any meaningful conclusion on the effect of the drug on
these events. Refractory ischemia was significantly less fre-
quent with diltiazem, and the drug prevented the need for
urgent intervention procedures. The survival curves diverged
early during hospitalization and further during the follow-up at
4 weeks. Consistent with the benefits to prevent recurrent
ischemia, patients who received diltiazem had less symptom-
based or elective intervention procedures and required less
intensive medical therapy with nitroglycerin, beta blockers and
an inhibitor of the angiotensin-converting enzyme.
Some imbalances were observed between the two study
groups, with larger infarcts in the diltiazem group as evaluated
at baseline by a greater amount of ST-segment elevation and a
larger perfusion defect score (40). These imbalances could
have had a negative impact on subsequent event rates with
diltiazem.
Effects of Diltiazem
The exact mechanisms by which diltiazem prevents recur-
rent ischemia are not explained by the present study. They may
be related to some effects on the complex interactions involv-
ing the underlying thrombogenic process, vascular reactivity
and shear stress at the site of the residual stenosis. Heart rate
and blood pressures were lower with treatment at all phases of
the study, and could have resulted in more favorable hemody-
namic conditions. The angiographic patency at 48 h, severity of
the residual stenoses, kinetics of CK and CK-MB and regional
and global left ventricular function early and late were not
influenced. The significantly greater gain in regional perfusion
and function observed with diltiazem may suggest better
regional perfusion and viability, but should be interpreted with
caution because it was associated with a larger initial defect,
which is one of the main determinants of the extent of recovery
(40).
The absence of benefits of diltiazem on infarct size con-
trasts with the results of experimental studies that have shown
a protective effect on the ischemic and reperfused myocardium
(1–14). However, when calcium antagonists were administered
late following coronary occlusion and during reperfusion, as in
this study and as in most clinical situations, the benefits
observed were less evident (2,7,10,14–16).
Limitations of the Study
This study was a pilot study and the small sample size
precludes any firm conclusions of the results. The findings
could be a chance effect and/or be explained by unrecognized
different baseline characteristics of the study population. The
event rate in the placebo group was high, but in the expected
range, with 10% mortality, 14% reinfarction, 24% recurrent
ischemia and 41% combined event rate. The methods of
investigation also lack sensitivity to detect modest effects of an
intervention. Strong correlation was, however, observed be-
tween the various enzymatic, electrocardiographic and radio-
nuclide markers of area at risk, infarct size and left ventricular
function. Diltiazem had neutral effects on these markers.
Recombinant t-PA was not used optimally and the more
effective accelerated regimen of administration could have
slightly improved the results, but very likely in a symmetrical
way in both study groups. Finally, the use of medical treatment
other than calcium antagonists (aspirin and heparin) was not
controlled, and more patients in the placebo group used
beta-blockers and angiotensin-converting enzyme inhibitors.
The benefits of diltiazem were additive, however, to those of
nitroglycerin administered in 71% and to those of beta-
blockers administered in 53% of patients. Less frequent use of
these drugs, or use of a smaller dose or a reduction of the doses
of diltiazem in their presence could possibly have amplified the
benefits of the drug, whereas it reduced the observed fre-
quency of bradyarrhythmia and hypotension.
Clinical Relevance
Diltiazem was relatively well tolerated in this study with no
more frequent congestive heart failure than placebo; the
complications associated with its use could be relatively easily
managed. The entry criteria were, however, strict, excluding
patients with clinically overt signs of left ventricular dysfunc-
tion or with an atrioventricular block. The deleterious effects
of diltiazem administration in patients with pulmonary edema
and congestive failure have been well documented in previous
clinical trials (41). Patients were also closely monitored in-
hospital with strict bedside orders to correct any eventual
bradycardia or hypotension. These side effects occurred fre-
quently, in two-third of the patients; they were considered
severe enough to require temporary reduction in dose in 20%
of patients and permanent discontinuation in 6.7%. Bleeding
risk could also be of concern. The five patients who developed
a hematoma at the site of femoral arterial puncture were in the
diltiazem group; this finding could be by chance or favored by
the antiplatelet effect of calcium antagonists. One retrospec-
tive analysis of factors predisposing to intracerebral hemor-
rhage with t-PA identified an association between the risk and
use of calcium antagonists at the time of myocardial infarction
(42).
The antiischemic effects were striking, resulting at 35 days
in a 14% reduction in the absolute risk of death, myocardial
infarction or refractory ischemia. Recurrent ischemia was the
only component of this composite endpoint that occurred
frequently enough to allow meaningful conclusions. The abso-
lute reduction in this end point exceeded 20%. The need for an
urgent intervention procedure was prevented and the total
number of interventions performed was reduced by 25% as
antianginal drugs were prescribed also less frequently. The use
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of diltiazem cannot be recommended based on the results of
our pilot study. The findings, however, shed some perspective
on the benefits to be expected from the use of calcium
antagonists in AMI and more specifically from diltiazem.
These findings may help orient future research such as benefits
to be expected, doses and methods of administration to
evaluate and on the investigation of better therapeutic strate-
gies for cell protection to improve the success of thrombolysis.
Some of the previous disappointment with these drugs may
have been due to excessive expectation on their potential
benefit, beyond their antiischemic effects, and also from as-
suming that the effects of the various calcium antagonists are
class-specific rather than drug-specific. This study and others
have not shown a clear benefit on infarct size. The protection
observed acutely with diltiazem against recurrent ischemia and
infarction was observed in trials of secondary prevention after
myocardial infarction with diltiazem and with verapamil
(24,43,44) outside of the context of thrombolysis. It was also
more recently described in a randomized double-blind trial of
intravenous diltiazem compared to intravenous glyceryl trini-
trate during the acute phase of unstable angina (45). In that
study, diltiazem reduced the risk of refractory angina and
myocardial infarction during the infusion by 62%. It would
therefore appear that the intravenous use of diltiazem might
be protective against the ongoing coronary pathophysiologic
processes involved with ischemia in acute coronary syndromes.
It cannot be extrapolated from our results, however, that the
benefits observed during the acute phase of myocardial infarc-
tion will extend beyond 36 days in long-term secondary pre-
vention.
We acknowledge the collaboration of the nursing staff of the Montreal Heart
Institute for the realization of the research work, of Datamed Inc. for the
statistical analyses, of Hoechst Marion Roussel for the financial support and of
Luce Be´gin for the secretarial work.
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